TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04033484

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
Study: NCT04013750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint Induced Movement Therapy
Description: constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint Induced Movement Therapy
Description: constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
Study: NCT01899053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 Capsules
Study: NCT00945555

Intervention type: DRUG
Intervention: Antibacterial agent for the treatment of febrile neutropenia
Description: The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
Study: NCT02532530

Intervention type: DEVICE
Group type: OTHER
Intervention: Near-Infrared Spectroscopy (NIRS)
Description: Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
Study: NCT01554358

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle intervention
Description: The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake \<30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~--------------------------------------------------------------------------------
Study: NCT02986438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Sham)
Description: The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks.
Study: NCT02712216

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: Determine best port sites to insert bariatric trocars
Study: NCT03151603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arctuvan
Description: application of a herbal drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: application of an antibiotic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Arctuvan
Description: application of Placebo to Arctuvan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Fosfomycin
Description: application of Placebo to Fosfomycin
Study: NCT04376008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard prostate biopsy
Description: Transperineal TRUS guided standard prostate biopsy (SB).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted and standard prostate biopsy
Description: Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
Study: NCT01726608

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of active versus sham radiofrequency neurotomy with Simplicity III

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of active versus sham radiofrequency neurotomy with Simplicity III
Study: NCT04155489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood transfusion
Description: In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started. in the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood transfusion
Description: In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started. in the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
Study: NCT04904679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana Vitrectomy with internal limiting membrane peeling
Description: The vitrectomy technique using pars plana 23-gauge will be performed with removal of the ILM (when present adhered to the macula) and placement of an amniotic membrane plug or a internal limiting membrane flap in the macular hole, with a fluid-air exchange and a buffering gas infusion (C3F8 12, 5%). The amniotic membrane plug will be made with a dermatological punch with a diameter of 1.0 to 2mm depending on the size of the macular hole measured by the OCT, and will be positioned inside de macular hole with the chorionic side facing the RPE ( retinal pigmented epithelium) with a 23 gauge forceps. The chorionic side of the membrane is the sticky one. The internal limiting membrane flap will be created at the same time of peeling and will bem positioned in as inverted flap over and inside the macular hole with a 23 gauge ILM forceps. These technics will be helped with de use of a extra lighting sclerotomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana Vitrectomy with internal limiting membrane peeling
Description: The vitrectomy technique using pars plana 23-gauge will be performed with removal of the ILM (when present adhered to the macula) and placement of an amniotic membrane plug or a internal limiting membrane flap in the macular hole, with a fluid-air exchange and a buffering gas infusion (C3F8 12, 5%). The amniotic membrane plug will be made with a dermatological punch with a diameter of 1.0 to 2mm depending on the size of the macular hole measured by the OCT, and will be positioned inside de macular hole with the chorionic side facing the RPE ( retinal pigmented epithelium) with a 23 gauge forceps. The chorionic side of the membrane is the sticky one. The internal limiting membrane flap will be created at the same time of peeling and will bem positioned in as inverted flap over and inside the macular hole with a 23 gauge ILM forceps. These technics will be helped with de use of a extra lighting sclerotomy.
Study: NCT03571633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab + Paclitaxel
Description: During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Paclitaxel
Description: During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
Study: NCT05222789

Intervention type: PROCEDURE
Intervention: TAP
Description: The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
Study: NCT03508440

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intratympanic injection
Description: Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intratympanic injection
Description: Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Steroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral Steroid
Study: NCT02014103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Administration of each formulation will be determined by sequence.
Study: NCT04110587

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: 1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Temporomandibular Joint Arthroscopy
Description: Lysis and Lavage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporomandibular Joint Arthroscopy
Description: Lysis and Lavage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic therapy
Description: Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic therapy
Description: Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
Study: NCT00662909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT04051619

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal oxytocin, 40 IU, twice a day for 7 days
Description: Adjunct therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin, 40 IU, twice a day for 7 days
Description: Adjunct therapy
Study: NCT03681639

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum Metal ion levels determined to monitor changes in chromium and cobalt levels
Description: Analyses was performed pre-operatively, 6 months, 1 year, 2 years and 5 years post-operatively for all study subjects enrolled in this study, as well as, all revision study subjects receiving the Metasul LDH™ total hip system. To prevent intra-observer variation the metal ion concentrations was analysed by an approved Central Laboratory. The Central Laboratory provided specimen collection kits for the transfer of blood specimens to the Laboratory for analysis. The Laboratory provided the results to the Investigators. The cobalt and chromium was measured by induced coupled plasma mass spectrometry (ICP-MS). BUN, creatinine and GFR will be determined locally.
Study: NCT02014103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Administration of each formulation will be determined by sequence.
Study: NCT01276067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10 mg Tablet
Study: NCT03342612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Magnetic Resonance Imaging (MRI)
Study: NCT04110587

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroid
Description: Dexamethasone, 4 mg I.V. (Intraoperative)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid
Description: Dexamethasone, 4 mg I.V. (Intraoperative)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiinflammatories
Description: Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiinflammatories
Description: Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Analgesics
Description: Metamizol 575 mg / 8h by mouth (Post-operatively)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: Metamizol 575 mg / 8h by mouth (Post-operatively)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise program
Description: Home exercise program
Study: NCT04227301

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling for measurement of bone markers after a fasting period of at least 6 hours
Study: NCT00931788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive agents and lipid lowering therapy
Description: The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
Study: NCT03380117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eBridge Online Counseling
Description: In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
Study: NCT01899053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Capsules
Study: NCT02177552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine

Intervention type: DRUG
Group type: OTHER
Intervention: Epirubicin

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Study: NCT00748787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Description: 1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
Study: NCT01505049

Intervention type: DRUG
Intervention: quadrivalent HPV vaccine
Description: For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
Study: NCT00982228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously once daily. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously once daily. Dose individually adjusted.
Study: NCT04110587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Home exercise program
Study: NCT02014103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Sandoz
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Sandoz
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Sandoz
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Sandoz
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Sandoz
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Sandoz
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Reddy Laboratory
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Reddy Laboratory
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Reddy Laboratory
Description: Administration of each formulation will be determined by sequence.
Study: NCT02112734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU/daily until age 12 months
Study: NCT02014103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Reddy Laboratory
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Reddy Laboratory
Description: Administration of each formulation will be determined by sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Reddy Laboratory
Description: Administration of each formulation will be determined by sequence.
Study: NCT03309150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred.